Drug class
Short-Acting Insulins
Short-acting insulins are a class of antidiabetic agents, primarily consisting of regular human insulin, designed to mimic physiologic mealtime insulin release. Read more about Short-Acting Insulins
71 drugs in this class 10 manufacturers
Drugs in Short-Acting Insulins
LYUMJEV U-100 INSULIN (insulin lispro-aabc)
LYUMJEV KWIKPEN U-100 INSULIN (insulin lispro-aabc)
LYUMJEV KWIKPEN U-200 INSULIN (insulin lispro-aabc)
NOVOLIN R REGULAR U-100 INSULN (insulin regular, human)
HUMULIN R REGULAR U-100 INSULN (insulin regular, human)
HUMALOG U-100 INSULIN (insulin lispro)
HUMALOG U-100 INSULIN (insulin lispro)
NOVOLOG U-100 INSULIN ASPART (insulin aspart)
Short-acting insulins are a class of antidiabetic agents, primarily consisting of regular human insulin, designed to mimic physiologic mealtime insulin release.
They work by binding to cellular insulin receptors, stimulating peripheral glucose uptake into skeletal muscle and adipose tissue while suppressing hepatic glucose production.
Typically demonstrating an onset of action within 30 to 60 minutes and a duration of about five to eight hours, this class is primarily indicated for glycemic control in type 1 and type 2 diabetes mellitus.
Additionally, short-acting regular insulin serves as a mainstay of intravenous therapy in acute metabolic emergencies such as diabetic ketoacidosis and hyperosmolar hyperglycemic states.
-
fda.gov
Short-acting insulins are a class of antidiabetic agents, primarily consisting of regular human insulin, designed to mimic physiologic mealtime insulin release Typically demonstrating an onset of action within 30 to 60 minutes and a duration of about five to eight hours, this class is primarily indicated for glycemic control in type 1 and type 2 diabetes mellitus
-
nih.gov
Short-acting insulins are a class of antidiabetic agents, primarily consisting of regular human insulin, designed to mimic physiologic mealtime insulin release Typically demonstrating an onset of action within 30 to 60 minutes and a duration of about five to eight hours, this class is primarily indicated for glycemic control in type 1 and type 2 diabetes mellitus Additionally, short-acting regular insulin serves as a mainstay of intravenous therapy in acute metabolic emergencies such as diabetic...
-
fda.gov
They work by binding to cellular insulin receptors, stimulating peripheral glucose uptake into skeletal muscle and adipose tissue while suppressing hepatic glucose production Additionally, short-acting regular insulin serves as a mainstay of intravenous therapy in acute metabolic emergencies such as diabetic ketoacidosis and hyperosmolar hyperglycemic states
-
fda.gov
They work by binding to cellular insulin receptors, stimulating peripheral glucose uptake into skeletal muscle and adipose tissue while suppressing hepatic glucose production
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.